A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE011 (ITA) · Dr. Jansen
consented 2022-05-26
Adverse events
Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2022-07-31 (study day 53); relationship: not assessed
Grade 2 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2022-08-01 (study day 54); relationship: not assessed
Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2022-10-24 (study day 138); relationship: Y
Grade 2 Neutropenia — outcome: UNKNOWN; onset 2022-11-01 (study day 146); relationship: N
Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2022-12-22 (study day 197); relationship: not assessed
Grade 1 Nausea — outcome: UNKNOWN; onset 2023-02-12 (study day 249); relationship: not assessed
Grade 2 Asthenia — outcome: RECOVERED/RESOLVED; onset 2023-06-19 (study day 376); relationship: not assessed
Grade 1 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-09-06 (study day 455); relationship: N
Grade 2 Stomatitis — outcome: RECOVERED/RESOLVED; onset 2023-09-09 (study day 458); relationship: not assessed
Data queries
No data queries.